5AM Ventures — Full Portfolio

Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for patients with autoimmune diseases.

BiotechHealthtechRadnor, US

Steven Nichtberger(Executive Officer, Director)Steven Nichtberger, MD(Founder)inDan Geffken(Executive Officer)Anup Marda(Chief Financial Officer)Mark Simon(Director)

Board seatBrian Daniels· per SEC Form D

BiotechCambridge, US

JOSH MANDEL-BREHM(Executive Officer, Director)RICHARD YOUNG(Director)

BoardMICHAEL HIGGINS(Director)JORGE CONDE(Director)inAMIR NASHAT(Director)in

Board seatAndrew J. SchwabAndy Schwab· per SEC Form D · filed Jun 2022

Co-investorsAndreessen HorowitzLongwood FundPolaris Partners

IDEAYA is a precision medicine oncology company developing first-in-class targeted therapies and rational drug combinations for molecularly defined, hard-to-treat cancers.

BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US

Yujiro Hata(Executive Officer, Director)Paul Stone(Executive Officer)in

BoardTimothy Shannon(Director)inTerry Rosen(Director)Jeffrey Stein(Director)

Board seatJohn DiekmanBrian Daniels· per SEC Form D

Co-investorsCanaan PartnersNextech Invest

Pulmatrix develops inhaled dry-powder therapies using its proprietary iSPERSE technology, which uses small, dense, dispersible particles to deliver respiratory and non-respiratory drugs via the respiratory system.

BiotechDeep TechHealthtechMedical DevicesFramingham, US

Anand Varadan(Director)Richard Batycky(Director)Peter Ludlum(Interim CEO; Interim CFO)Hojabr Alimi(Executive Officer)Sameer Harish(Executive Officer)

BoardRichard Conley(Director)

Board seatScott Rocklage· per SEC Form D

Co-investorsARCH Venture PartnersPolaris Partners

Rallybio is a clinical-stage biotech company developing therapies for people with severe and rare diseases, with a pipeline focused on complement dysregulation and hematology.

BiotechHealthtechNew Haven, US

Steve Uden(Co-Founder & Chief Executive Officer)Stephen Uden(Founder)inMartin(Co-Founder & Chairman)Jon(Chief Financial Officer)

Board seatKush M ParmarPaula Soteropoulos· per SEC Form D

Co-investorsCanaan PartnersConnecticut InnovationsF-Prime CapitalMitsui Global InvestmentSolasta Ventures

BiotechBedford, US

Huw Nash(Executive Officer)Adrian Krainer(Executive Officer, Director, Promoter)Isabel Aznarez(Executive Officer, Director, Promoter)

Board seatArthur Tzianabos· per SEC Form D · $90M raise · filed Nov 2018

Arvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology.

BiotechHealthtechNew Haven, US

Sean Cassidy(Executive Officer)Manuel Litchman(Executive Officer, Director)

BoardStephen Squinto(Director)inLiam Ratcliffe(Director)inTim Shannon(Director)inKush Parmar(Director)

Co-investorsAccess BiotechnologyCanaan PartnersConnecticut InnovationsNextech InvestRA CapitalSolasta Ventures+1 more

Enliven Therapeutics is a biopharmaceutical company developing small molecule precision therapeutics, including ELVN-001, a selective active site inhibitor of BCR::ABL1 for patients with chronic myeloid leukemia (CML).

BiotechHealthtechBoulder, US

Co-investorsOrbiMedPfizer Venture InvestmentsRoche Venture FundARCH Venture Partners

Co-investorsOUP (Osage University Partners)RA Capital

Kinaset Therapeutics is a drug developer working on KN-002, a therapeutic candidate for treating severe asthma across patients regardless of the underlying cause of inflammation.

BiotechHealthtechMedfield, US

Roger Heerman(Chief Business/Operating Officer / Co-Founder)Frazer Morgan(Chief Development Officer / Co-Founder)Robert Clarke(Chief Executive Officer / Board Member / Co-Founder)Christopher O’Brien(Chief Medical Officer)

BoardJamil Beg(Director of the Issuer)inTom King(Director of the Issuer)

Co-investorsAtlas VentureRA CapitalEQT Life SciencesSixty Degree CapitalVivo CapitalGimv+1 more

Lifordi Immunotherapeutics develops treatments for immunology and rare diseases through discovery, clinical development, and commercialization.

BiotechDeep TechHealthtech

Arthur O. Tzianabos, Ph.D.(President and CEO)Naina Bhasin, Ph.D.(Chief Business Officer)

Co-investorsARCH Venture PartnersAtlas VentureSanofi Ventures

Precede Biosciences develops a blood-based diagnostic platform that profiles gene expression from cell-free DNA to reveal disease biology at the transcriptional level for drug developers and clinical trials.

AI & Machine LearningBiotechDigital HealthBoston, US

Rehan Verjee(Co-Founder, Chief Executive Officer, Board Director)Sylvan Baca(Co-Founder; Assistant Professor of Medicine, Dana-Farber Cancer Institute)Toni Choueiri(Co-Founder; Director, Lank Center for GU Oncology, Dana-Farber Cancer Institute)Matthew Freedman(Co-Founder; Professor of Medicine, Dana-Farber Cancer Institute)

Co-investorsIllumina VenturesOUP (Osage University Partners)Lilly Asia VenturesOsage University Partners

BlueLight Therapeutics uses a proprietary platform based on Second Harmonic Generation (SHG) to measure real-time structural changes of biomolecules, applying this structure-driven approach to discover and develop therapeutic molecules for difficult-to-drug, high-value targets.

BiotechDeep TechSouth San Francisco, US

Co-investorsPfizer VenturesPfizer Venture Investments

BiotechCambridge, US

G. Houston Hall(Manager of the Issuer)Adrian Z. Stecyk(Manager of the Issuer)Mark J. Pykett(Manager of the Issuer)

BoardAlexander M. Seaver(Manager of the Issuer)

Board seatArthur Tzianabos· per SEC Form D · $5M raise · filed Feb 2016

Akouos is a precision genetic medicine company developing therapies for the inner ear to restore, improve, and preserve hearing.

BiotechHealthtechBrookline, US

Emmanuel Simons(Executive Officer, Director)william sewell(Founder)in

BoardEd Mathers(Director)inKush Parmar(Director)in

Board seatKush M ParmarArthur Tzianabos· per SEC Form D

Co-investorsEcoR1 CapitalNew Enterprise Associates (NEA)RA CapitalSofinnova VenturesCowen Healthcare InvestmentsFidelity Investments+1 more

Artiva Biotherapeutics is a clinical-stage biotechnology company developing natural killer (NK) cell-based therapies for patients with autoimmune diseases.

BiotechHealthtechSan Diego, US

Jennifer Bush(Executive Officer)Yong-Jun Huh(Director)Thomas J. Farrell(Executive Officer)Yu-Kyeong Hwang(Director)Fred Aslan(Executive Officer, Director)Jason Litten(Executive Officer)

Board seatBrian Daniels· per SEC Form D

Co-investorsEcoR1 CapitalRA CapitalvenBio PartnersvenBio Global Strategic

La Jolla, US

Richa Nand(Executive Officer)Alan Glicklich(Executive Officer)Mark Saad(Executive Officer)Paul A. Grayson(Executive Officer, Director)Erik Karrer(Executive Officer)Ray Stevens(Director)

Board seatAndrew J. Schwab· per SEC Form D

Co-investorsSR One Capital Management

Pharmaceutical company developing medicines and vaccines for patient health and treatment.

BiotechHealthtechSan Diego, US

Jeffrey Stein(Executive Officer, Director)Kevin Judice(Director)inKevin Forrest(Executive Officer)Dirk Thye(Executive Officer)Ken Bartizal(Executive Officer)Paul Daruwala(Executive Officer)

Board seatScott Rocklage· per SEC Form D

Co-investorsAisling CapitalBain Capital Life SciencesFrazier Life SciencesRA CapitalVivo CapitalCanaan Partners+1 more

Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment.

BiotechHealthtechMedical DevicesBoston, US

Board seatKush M ParmarPaula Soteropoulos· per SEC Form D

Co-investorsAju IB Invesment CorporationCatalio Capital Management, LPDelos CapitalF-Prime CapitalSolasta VenturesAlexandria+7 more

BiotechBurlingame, US

John Celebi(Executive Officer)Mary Haak-Frendscho(Executive Officer, Director)

BoardCarl Gordon(Director)inDavid Goeddel(Director)Robert Schreiber(Director)

Board seatJohn Diekman· per SEC Form D · $6.3M raise · filed Jan 2015

Co-investorsOrbiMedThe Column Group

South San Francisco, US

Geoffrey Richardson(Executive Officer)Howard Turner(Executive Officer, Director)

BoardDipender Saluja(Director)Sam Bergh(Director)Suk-Bae Cha(Director)

Board seatScott Rocklage· per SEC Form D · $54.6M raise · filed Jun 2018

Co-investorsTechnology Impact

Latigo Bio is a clinical-stage biopharmaceutical company developing non-opioid pain medicines intended to block pain transmission without addiction risk.

BiotechHealthtechThousand Oaks, US

Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)

BoardBeth Seidenberg(Director)inJim Tananbaum(Director)Kevin Raidy(Director)

Board seatDeborah Palestrant· per SEC Form D · $150M raise · filed Feb 2025

Co-investorsAccess BiotechnologyForesite CapitalKern Capital, LLCSanofi VenturesWestlake Village BioPartners

Pioneering the development of prescription digital therapeutics.

HealthtechBoston, US

Corey McCann(Executive Officer, Director)Antoun Nabhan(Executive Officer)Christopher Guiffre(Executive Officer)

BoardAndrew Schwab(Director)inTimothy Petersen(Director)inZack Lynch(Director)in

Board seatAndrew J. Schwab· per SEC Form D · $20.4M raise · filed Feb 2016

Co-investorsJAZZ Venture PartnersArboretum VenturesGeneral CatalystOCA VenturesSeyen CapitalSoftBank Group+1 more

BiotechVancouver

Andrew Booth(Director)Andrew J. Schwab(Director)inR. James Taylor(Executive Officer, Director)Joe Victor(Executive Officer, Director)Euan Ramsay(Executive Officer)Daniel Nixon(Director)

Board seatAndrew J. Schwab· per SEC Form D · $13.4M raise · filed Nov 2016

Co-investorsRising TideTelegraph Hill Partners

BiotechLexington, US

Robert Clarke(Chief Executive Officer and Member of the Board of Directors)David Hava(Chief Scientific Officer)David Edwards(Director)

BoardSteven Gillis(Director)Terrance McGuire(Director)David Maki(Director)

Board seatScott Rocklage· per SEC Form D · $34.1M raise · filed Jun 2015

Co-investorsPolaris Partners

BiotechPleasanton, US

Bill W. Colston, Ph.D.(Director)Klint Rose, Ph.D.(Chief Scientific Officer)Barney E. Saunders,Ph.D.(Chief Executive Officer)Steve Reichenbach(Chief Financial Officer)Joseph J. Victor(Executive Chairman of the Board of Directors)Juan G. Santiago(Executive Officer, Director, Promoter)

Board seatJoseph J. Victor· per SEC Form D

Co-investorsCota CapitalRoche Venture Fund

Seattle, US

Ronald Seubert(Executive Officer, Director, Promoter)Evan Castiglia(Executive Officer)Joseph Victor(Executive Officer, Director)Frank Witney(Director)Eric Kaldjian(Executive Officer)

BoardRobert Shepler(Director)in

Board seatAndrew Schwab· per SEC Form D

Co-investorsArboretum VenturesF-Prime CapitalSofinnova VenturesTelegraph Hill Partners

Santa Clara, US

Thomas Boussie(Executive Officer)John Borkholder(Executive Officer)Robert Wedinger(Executive Officer, Director)Michelle Cheung(Executive Officer)Vince Murphy(Executive Officer)

BoardSamuel Colella(Director)

Board seatScott Rocklage· per SEC Form D

Co-investorsFrazier Life SciencesSofinnova Ventures

Alexza Pharmaceuticals, now operating as Nova Pneuma, Inc., is a pharmaceutical company that developed the Staccato One Breath Technology drug-delivery platform and markets the commercial product Adasuve.

BiotechHealthtechMountain View, US

Edwin S Kamemoto(Executive Officer)Mark K Oki(Executive Officer)Thomas B King(Executive Officer, Director)Michael J Simms(Executive Officer)James V Cassella(Executive Officer)Robert A Lippe(Executive Officer)

Co-investorsNew Enterprise Associates (NEA)

Co-investorsM Ventures

Co-investorsForesite Capital

Bioz provides AI-powered widgets for suppliers that display scientific publication data to build trust and improve sales conversion.

AI & Machine LearningEnterprise SoftwareSaaSLos Altos, US

Daniel Levitt(Executive Officer, Director)Karin Lachmi(Executive Officer, Director)Karin L.(Founder)in

Co-investorsPerot Jain

Co-investorsFrazier Life Sciences

Camp4 is a biotechnology company focused on genetic research and neurology, leveraging expertise in genomics and neuroscience for therapeutic development.

AI & Machine LearningBiotech

BoardChristopher Walsh, MD, PhD(Scientific Advisor)

Co-investorsAndreessen HorowitzFlucas Ventures

Co-investorsSofinnova Ventures

BiotechBurlingame, US

Mark Rolfe(Executive Officer)Laura Shawver(Executive Officer, Director)Timothy Smith(Executive Officer)

BoardAlfred Scheidegger(Director)inPeter Thompson(Director)Carol Gallagher(Director)

Co-investorsAstellas Venture Management LLCNew Enterprise Associates (NEA)Nextech InvestClarus VenturesOrbiMedOsage University Partners+1 more

Crinetics is a pharmaceutical company focused on discovering, developing, and commercializing therapies for endocrine diseases and endocrine-related conditions.

Biotech

Co-investorsOrbiMedRA Capital

Dianthus Therapeutics develops antibody-based therapies for patients with severe autoimmune diseases, including its lead complement C1s inhibitor claseprubart (DNTH103) and a bifunctional inhibitor DNTH212 designed for self-administered subcutaneous injection.

BiotechHealthtechWaltham, US

Jonathan Violin(Executive Officer, Director)Kenneth Evan Thompson(Executive Officer)

BoardLeon Moulder(Director)

Directed energy systems using AI-orchestrated high-power microwaves for electromagnetic defense.

Co-investorsBVVCCenter15 CapitalDCVC (Data Collective)Inflection VenturesManhattan Venture PartnersNightDragon+2 more

BiotechDel Mar, US

Matthew Disney(Director)Paul Stone(Executive Officer)inYujiro Hata(Director)Kevin Forrest(Executive Officer, Director)

BoardScott Rocklage(Executive Officer, Director)inJason Hafler(Director)in

Co-investorsKleiner PerkinsNovartis Venture FundSanofi Ventures

GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs.

BiotechHealthtechNewton, US

Ganesh V. Kaundinya(President & CEO)in

Co-investorsCatalio Capital Management, LPLifeArc VenturesRoche Venture FundSixty Degree CapitalSofinnova PartnersAgent Capital+1 more

Hayward, US

Co-investorsTechnology Impact

Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.

BiotechBedford, US

Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)

BoardSteven Gillis(Director)Arthur Tzianabos(Executive Officer, Director)Kush Parmar(Director)inRichard Gregory(Director)

Co-investorsARCH Venture PartnersOUP (Osage University Partners)AlexandriaDeerfield Management CompanyHBM Healthcare InvestmentsMaverick Ventures+4 more

Co-investorsUS Venture Partners

HealthtechSeattle, US

John D. Hoekman(Executive Officer, Director)

BoardMichael Hite(Director)Stewart Parker(Director)

Co-investorsB Capital GroupvenBio Global StrategicvenBio PartnersWestlake Village BioPartners

Inipharm is a clinical-stage biopharmaceutical company developing small-molecule inhibitors targeting HSD17B13 to treat severe fibrotic liver diseases, including MASH and other conditions with established genetic validation.

BiotechHealthtechMedical Devices

Chuhan Chung(Chief Medical Officer)

Co-investorsFrazier Life Sciences

The page promotes "MEGA55", an Indonesian-language online gaming/gambling platform offering a variety of games with instant-win rewards and local digital payment methods.

Gaming

Co-investorsSanofi Ventures

Karius is a company that provides microbial cell-free DNA (mcfDNA) metagenomic sequencing services for research and clinical applications.

AI & Machine LearningBiotechDigital HealthMedical DevicesSan Francisco, US

Alec Ford(Chief Executive Officer)

Co-investorsDCVC (Data Collective)Khosla VenturesLightspeed Venture PartnersSoftBank Vision Fund

Magnetic Insight develops magnetic particle imaging technology that uses non-radioactive tracers as an alternative to conventional radioactive tracers used in nuclear medicine scans.

Deep TechHealthtechMedical Devices

Co-investorsInnolinks VenturesShangBay Capital LLC

Co-investorsLongwood Fund

nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.

BiotechDeep TechMedical Devices

Luke Gilbert, PhDKeith Joung, MD, PhDDavid Liu, PhDAngelo Lombardo, PhDLuigi Naldini, MD, PhDJonathan Weissman, PhD

Co-investorsAtlas VentureNewpath PartnersARCH Venture PartnersDCVC (Data Collective)F-Prime CapitalDCVC Bio+1 more

Neurogastrx is a late clinical-stage biopharmaceutical company developing therapies for patients with serious gastrointestinal (GI) disorders that have limited treatment options.

BiotechHealthtechWoburn, US

Cyril De Colle(Founder)inCYRIL DE COLLE(Executive Officer, Director)JAMES DETORE(Executive Officer)JAMES O'MARA(Executive Officer, Director)PAUL ROGERS(Executive Officer)

BoardDAVID ALLISON(Director)

Co-investorsOrbiMedSamsara BioCapitalvenBio PartnersVivo CapitalvenBio Global StrategicWestlake Village BioPartners

NodThera develops clinical-stage small-molecule therapies targeting inflammation for cardiometabolic and neuroinflammatory diseases, including cardiovascular disease, metabolic dysfunction, and neuroinflammation.

BiotechHealthtech

Geoff McDonough(Executive Team / Board)Chris Guiffre(Executive Team)Alan P. Watt(Executive Team)Jyothis George(Chief Medical Officer)Nick Clarke(Executive Team)

Co-investorsEpidarex CapitalF-Prime CapitalSanofi VenturesSofinnova Partners

Co-investorsAndera PartnersAngelini VenturesCDP Venture CapitalIndaco Venture PartnersM VenturesXGEN Venture

BiotechDoylestown, US

Osvaldo Flores(Executive Officer, Director)Daniel E. Geffken(Executive Officer)George Hartman(Executive Officer)Gregory Korbel(Executive Officer)

BoardTim Shannon(Director)Scott Rocklage(Director)

Co-investorsBioAdvanceCanaan PartnersVersant Ventures

South San Francisco biotech engineering commensal gut bacteria into controllable live therapeutics for chronic diseases.

Daly City, US

Weston Whitaker(Executive Officer, Director, Promoter)William DeLoache(Director)Samuel Smits(Director)

BoardElizabeth Stanley(Director)

Co-investorsAlta PartnersCerity Partners VenturesDCVC Bio

BiotechSeattle, US

ROBERT W. OVERELL(Executive Officer, Director, Promoter)PAUL JOHNSON(Executive Officer, Director)Michael Houston(Executive Officer)Andrew Leon(Executive Officer)Robert W. Overell(Executive Officer, Director, Promoter)Paul H. Johnson(Executive Officer, Director)

Radionetics develops small molecule radiopharmaceuticals that target GPCRs, using radioisotope-tethered ligands to image and treat cancerous tumors as part of a theranostics precision medicine approach.

BiotechMedical DevicesSan Diego, US

Co-investorsFrazier Life Sciences

Co-investorsHEALTHCARE ROYALTY PARTNERS

Renasant Bio is a biopharmaceutical company developing oral small molecule corrector and potentiator therapies to restore the function of polycystin 1 and 2 proteins in autosomal dominant polycystic kidney disease (ADPKD).

BiotechHealthtechBerkeley, US

Jeremy Reiter(Scientific Co-Founder)Markus Delling(Scientific Co-Founder)Thomas Gustafson(Executive Officer)Emily Conley(Executive Officer, Director)

BoardEvan Caplan(Director)inCharlotte McKee(Director)

Co-investorsOrbiMedAtlas VentureQiming Venture Partners USA

BiotechLexington, US

Pieter Muntendam(Executive Officer, Director)

BoardMette Kirstine Agger(Director)Kush Parmar(Director)inDorothy Coleman(Director)Leonard Schaeffer(Director)

BiotechSouth San Francisco, US

Anna Berkenblit(Director)Harold Varmus(Director)

BoardDavid Goeddel(Director)Craig Parker(Executive Officer, Director)Tim Kutzkey(Director)

Co-investorsThe Column Group

BiotechSan Diego, US

Alain Baron(Executive Officer, Director)JeenJoo Kang(Director)Robert Tjian(Director)Marcus Boehm(Executive Officer)

BoardAndrew Schwab(Director)in

Co-investorsAvego BioScience CapitalNew Enterprise Associates (NEA)OUP (Osage University Partners)Sanofi VenturesThe Column GroupAbingworth+3 more

TMRW Life Sciences builds an FDA-cleared automated platform for managing and storing frozen eggs and embryos, using RFID tracking and an "ivfOS" digital database to monitor and secure specimens.

Digital HealthFemTechHealthtechMedical DevicesNew York, US

Joshua Abram(Director)inTara Comonte(Director)Alan Murray(Director)

BoardAndrew Schwab(Director)Vinay Shah(Director)Emily Drabant Conley(Director)

Co-investorsGV (Google Ventures)

VBI Vaccines is a biopharmaceutical company developing vaccine candidates using virus-like particle (VLP) platforms, including proprietary enveloped VLP and mRNA-launched eVLP technologies.

BiotechHealthtechCambridge, US

Marc Kirchmeier(Vice President, Formulation Development)Egidio Nascimento(Chief Financial Officer)David Anderson(Senior Vice President, Research)Jeff Baxter(President and Chief Executive Officer)Adam T. Buckley(Vice President, Business Development)Murray G. Smith(Executive Officer)

Co-investorsARCH Venture PartnersClarus VenturesK2 HealthVentures

Viveve publishes evidence-based health and wellness guides for general readers across six topic areas including heart health, women's health, nutrition, hormones, sexual health, and aging.

Digital HealthMedia & EntertainmentWellness & Fitness

Co-investorsAvoro Capital Advisors